Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
60 participants
INTERVENTIONAL
2022-12-25
2024-01-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
So this study aims to evaluate the efficacy of trivalent chromium supplementation in rheumatoid arthritis treatment and measuring the outcomes of that in rheumatoid arthritis patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Can Creatine Supplementation Improve Body Composition and Physical Function in Rheumatoid Arthritis Patients?
NCT01767844
Investigation Of The Effects Of Anti-Tnf-Α And Non-Tnf-Α Drugs İn Patients With Rheumatoid Arthritis
NCT07182630
The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients
NCT06640309
Effectiveness of Therapeutic Fasting and Specific Diet in Patients With Rheumatoid Arthritis
NCT03856190
Role of L-Arginine Supplementation in the Treatment of Rheumatoid Arthritis
NCT04535427
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Trivalent chromium
A dietary supplement already available in market one of its known uses is to control diabetes.
Trivalent chromium versus synthetic and/ or biological DMARDs
Supplement and immunesuppressants
Immunesuppressants
Synthetic and/ or biological DMARDs
Trivalent chromium versus synthetic and/ or biological DMARDs
Supplement and immunesuppressants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trivalent chromium versus synthetic and/ or biological DMARDs
Supplement and immunesuppressants
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sally Saad Saad Hassouna
Lecturer of Internal Medicine department, Rheumatology and Immunology Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, Alexandria University, Egypt
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hassouna SS, Sheta E, Zaki I, Harby SA, Allam EA. Trivalent chromium supplementation ameliorates adjuvant induced rheumatoid arthritis through up-regulation of FOXP3 and decrease in synovial Cathepsin G expression. Inflammopharmacology. 2022 Dec;30(6):2181-2195. doi: 10.1007/s10787-022-01025-8. Epub 2022 Jul 13.
Hassouna SS, Abdel-Moniem OM. Trivalent chromium versus baricitinib for rheumatoid arthritis treatment: first phase 2/3 randomized controlled trial, is trivalent chromium the upcoming immune-modulator? Inflammopharmacology. 2024 Oct;32(5):3163-3179. doi: 10.1007/s10787-024-01515-x. Epub 2024 Jul 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
040457
Identifier Type: REGISTRY
Identifier Source: secondary_id
Trivalent chromium treatment
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.